Your browser doesn't support javascript.
loading
Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.
AlRuthia, Yazed; Hani Aburisheh, Khaled; Ata, Sondus; Bin Salleeh, Raghad; Alqudhibi, Shahad B; Alqudhibi, Raghad B; Alkraidis, Ziad; Humood Alkhalaf, Hala; Abdullah Almogirah, Abdulrahman; Mujammami, Muhammad; Al Khalifah, Reem.
Afiliação
  • AlRuthia Y; Department of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
  • Hani Aburisheh K; Pharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Ata S; University Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
  • Bin Salleeh R; Department of Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia.
  • Alqudhibi SB; Department of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
  • Alqudhibi RB; Department of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
  • Alkraidis Z; Department of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
  • Humood Alkhalaf H; Department of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
  • Abdullah Almogirah A; Department of Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia.
  • Mujammami M; Division of Endocrinology, Department of Medicine, Security Forces Hospital, Riyadh, Saudi Arabia.
  • Al Khalifah R; University Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
Saudi Pharm J ; 32(5): 102057, 2024 May.
Article em En | MEDLINE | ID: mdl-38601976
ABSTRACT

Introduction:

Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), is often prescribed for managing type 2 diabetes, particularly in cases unresponsive to other hypoglycemic agents. Despite its popularity, the real-world efficacy and cost-effectiveness of Semaglutide relative to other treatments remain understudied.

Objective:

This study aimed to examine the direct medical cost and consequences of adding Semaglutide to the treatment regimen for patients with type 2 diabetes in Saudi Arabia.

Methods:

We conducted a single-center, retrospective review of Electronic Medical Records (EMRs) for adults with type 2 diabetes. Patients who had been on Semaglutide for at least three months were matched with those receiving alternative hypoglycemic therapies. Exclusions were made for patients with cancer, incomplete EMRs, or lacking prescription data. Investigated outcomes included changes in HbA1C levels and weight, and the direct costs comprised medications, clinic visits, and emergency care. Baseline adjustments were made through inverse probability treatment weighting, and uncertainty was assessed via bootstrapping with 10,000 replications.

Results:

Out of 350 patients meeting the criteria, 116 were on Semaglutide. Predominantly females (62%), the cohort had an average age of 60 and a disease duration of 22 years. The difference in HbA1C (%) reductions between Semaglutide and non-Semaglutide users over 3,6, and 12 months were 0.154 (95% CI -0.452-0.483), -0.031(95% CI -0.754-0.239), -0.16(95% CI -1.425-0.840), respectively. Semaglutide users did experience modest weight reductions ranging from 0.42 kg to 1.16 kg. The annual additional direct medical cost for Semaglutide was USD 4,086.82 (95% CI $3,710.85 - $4,294.99).

Conclusion:

Although Semaglutide induced modest weight reductions, it did not offer significant advantages in lowering HbA1C levels compared to other hypoglycemic treatments. These findings suggest the need for further research involving larger and more diverse cohorts to corroborate these findings.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article